BioCentury | Apr 23, 2015
Distillery Techniques

Techniques: Antibody-based protease inhibitors

...of the antibody with published values of Elafin. Proteo Inc. and Minapharm Pharmaceutical S.A.E. have Elafin...
BioCentury | Dec 22, 2014
Company News

Proteo management update

...Inc. (OTCQB:PTEO), Irvine, Calif. Business: Pulmonary, Cardiovascular, Inflammation Hired: Juergen Paal as COO of Proteo’s Proteo...
BioCentury | Dec 8, 2014
Clinical News

Elafin: Phase II data

...patients undergoing coronary artery bypass graft (CABG) surgery showed that a single pre-operative dose of Elafin...
...did not significantly reduce plasma troponin I AUC from 0-48 hours after surgery vs. placebo. Proteo...
...Aug. 13, 2007). Proteo Inc. (OTCQB:PTEO), Irvine, Calif. Minapharm Pharmaceuticals S.A.E. , Cairo, Egypt Product: Elafin...
BioCentury | May 26, 2014
Company News

Proteo, Biotech Development Corp. deal

...will provide up to €3.5 million ($4.8 million) in funding to support development of Proteo's Elafin...
...the product in the indication. Elafin has completed Phase II testing for the indication, and Proteo...
...to treat esophagus carcinoma and in the U.S. to prevent inflammatory complications of transthoracic esophagectomy. Elafin...
BioCentury | Nov 18, 2013
Clinical News

Elafin: Completed Phase II enrollment

...coronary bypass surgery in the double-blind, placebo-controlled, U.K. Phase II EMPIRE trial evaluating intraoperative Elafin. Proteo...
...treat inflammation following esophagectomy for esophagus carcinoma. Minapharm has exclusive rights to develop and commercialize Elafin...
...China and Taiwan. Proteo Inc. (OTCQB:PTEO), Irvine, Calif. Minapharm Pharmaceuticals S.A.E. , Cairo, Egypt Product: Elafin...
BioCentury | Aug 22, 2013
Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Polypeptide N-acetylgalactosaminyltransferase (GALNT; GalNac-T) Patient sample, cell culture and mouse studies suggest inhibiting GALNT could help treat cancer. Addition of...
BioCentury | May 23, 2013
Distillery Therapeutics

Indication: Cancer

...Y. et al. Blood; published online May 2, 2013; doi:10.1182/blood-2012-11-465971 Contact: Hiroshi Fujiwara, Ehime University Proteo-medicine...
BioCentury | Apr 1, 2013
Clinical News

Elafin regulatory update

...for Elafin to prevent inflammatory complications of transthoracic esophagectomy, a surgical procedure for esophageal cancer. Elafin...
...and EU to treat pulmonary arterial hypertension (PAH), for which it is in preclinical testing. Elafin...
...Aug. 13, 2007). Proteo Inc. (OTCQB:PTEO), Irvine, Calif. Minapharm Pharmaceuticals S.A.E. , Cairo, Egypt Product: Elafin...
BioCentury | Jan 14, 2013
Clinical News

Elafin regulatory update

...FDA granted Orphan Drug designation to Elafin for the treatment of pulmonary arterial hypertension (PAH). Elafin...
...surgery, and to prevent acute organ rejection and chronic graft injury in kidney transplant patients. Elafin...
...under a 2007 deal (see BioCentury, Aug. 13, 2007). Proteo Inc. (OTCQB:PTEO), Irvine, Calif. Product: Elafin...
BioCentury | Dec 24, 2012
Clinical News

Elafin: Phase II ongoing

...coronary bypass surgery in the double-blind, placebo-controlled, U.K. Phase II EMPIRE trial evaluating intraoperative Elafin. Proteo...
...treat inflammation following esophagectomy for esophagus carcinoma. Minapharm has exclusive rights to develop and commercialize Elafin...
...China and Taiwan. Proteo Inc. (OTCQB:PTEO1), Irvine, Calif. Minapharm Pharmaceuticals S.A.E. , Cairo, Egypt Product: Elafin...
Items per page:
1 - 10 of 28